Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine. Issue 5 (September 2021)

• Record Type: Journal Article
• Authors: Rahman, Rifaquat
• Is Part Of: Cancer journal. Volume 27:Issue 5(2021)
• Publication Date: 2021-09
• Subjects: Adaptive platform trial -- biomarkers -- clinical trial design -- glioma; Cancer -- Periodicals; 616.994005
• DOI: 10.1097/PPO.0000000000000549
• Languages: English
• ISSNs: 1528-9117

Abstract

Abstract : Abstract: In the era of precision medicine, there is a desire to harness our improved understanding of genomic and molecular underpinnings of gliomas to develop therapies that can be tailored to individual patients and tumors. With the rapid development of novel therapies, there has been a growing need to develop smart clinical trials that are designed to efficiently test promising agents, identify therapies likely to benefit patients, and discard ineffective therapies. We review clinical trial design in gliomas and developments designed to address the unique challenges of precision medicine. To provide an overview of this topic, we examine considerations for endpoints and response assessment, biomarkers, and novel clinical trial designs such as adaptive platform trials in the testing of new therapies for glioma patients.